Comanche Biopharma secured an additional $40 million to advance an siRNA injectable program aimed at treating preeclampsia—the company says the funding will enable initiation of human trials across multiple sites. The capital is positioned to move the potential first‑ever targeted preeclampsia therapy toward clinic entry. The financing reflects investor interest in RNA therapeutics beyond classical indications and sets a clock on early clinical validation for a condition with high maternal‑fetal morbidity. Comanche will need to demonstrate safety and dosing in pregnant populations, a regulatory and ethical testing area with elevated scrutiny.